23ME-01473

N/A

Report date: 2024/12/05 20:00:05

Base Information

Drug Name23ME-01473

Drug Alias Name23ME-01473‘1473

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionRetinoic Acid Early Transcript 1L modulators

TargetsRetinoic Acid Early Transcript 1L

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator Companies23andme Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive Companies23andme Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

ATC CodeN/A